Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Thrombosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Thrombosis
    Smoking and Obesity Are Major Risk Factors for Thromboembolic Events: Presented at AHA - (DGDispatch)
    Rivaroxaban Reduces Risk of Venous Thrombosis Following Hip, Knee Surgeries: Presented at AHA - (DGDispatch)
    Darbepoetin Alfa Risky for Type 2 Diabetics With Kidney Disease: Presented at AHA - (DGDispatch)
    Community Practice Study Confirms Association Between ESAs, Venous Thromboembolism - (DGNews)
    Study Challenges Association Between Pulmonary Embolism and DVT - (DGNews)

    News archive

     Recent webcasts/CME - Thrombosis
    • Managing Treatment- and Disease-Related Complications in Multiple Myeloma
    • Thrombosis in Multiple Myeloma: Choice of Thromboprophylaxis Depends on Type of Therapy and Individual Risk of Patient
    • Peripheral Neuropathy in Multiple Myeloma: Early Recognition and Intervention Key to Minimize Long-Term Complications
    • Myeloma Bone Disease: Is Targeting of Osteoclastic and Osteoblastic Mechanisms Necessary for Effective Therapy?
    • Update on DVT and PE in OB Gyn/Ortho Patients

      Webcasts/CME archive

       Recent cases - Thrombosis
        Abscess of the Round Ligament of the Liver Associated with Acute Obstructive Cholangitis and Septic Thrombosis
        Multiorgan Paradoxical Embolism Consequent to Acute Pulmonary Thromboembolism with Patent Foramen Ovale: A Case Report
        Thrombotic Thrombocytopenic Purpura Complicated with Hypereosinophilic Syndrome
        Assessment of Specific Risks for the Recurrence of Deep Vein Thrombosis: A Case Report
        Pancreatic Carcinoma Associated with Portal Vein Tumor Thrombus: Three Case Reports

        Cases archive
          




        my personal edition > thrombosis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Enoxaparin Given at Home for Deep Vein Thrombosis More Efficacious and Less Expensive than Unfractionated Heparin Given in Hospital: Presented at ASH

        By Bruce Sylvester

        PHILADELPHIA, PA -- December 11, 2002 -- Treatment of symptomatic deep-vein thrombosis (DVT) with once-daily enoxaparin at home is as safe, more effective and less expensive than treatment with unfractionated heparin (UFH) in the hospital, researchers report.

        "This is the first study to use and compare these regimens using one dose a day," said Beng Chong, MD, investigator and professor of medicine at St. George Hospital, University of New South Wales School of Medicine, in Sydney, Australia. "It was much more convenient than in a prior study where they used twice-daily dosing at home and in the hospital. This is particularly important if you have to send a nurse to a patient's home to administer a drug. It is also clearly less expensive and more efficacious to use enoxaparin."

        The research was presented here this week at the annual meeting of the American Society of Hematology.

        Dr. Chong's team enrolled subjects with lower extremity symptomatic DVT confirmed by venogram/ultrasonogram in a prospective, multicentre, open, randomized, controlled study designed to compare the efficacy and safety of once-daily enoxaparin treatment at home with continuous unfractionated heparin (UFH) infusion in hospital for the treatment of DVT.

        The subjects received for at least five days either 1.5 mg/kg enoxaparin (150 patients) once daily subcutaneously at home or continuous infusion with UFH (148 patients) in hospital. The researchers administered warfarin to all subjects at baseline and for the next three months.

        The investigators used Australian cost data to evaluate the treatment regimens (direct and indirect cost). They assessed efficacy endpoints (including recurrent symptomatic DVT and pulmonary embolism) up to 24 weeks following treatment, confirming efficacies with venography/ultrasonography and ventilation/perfusion lung scanning.

        Safety end-points included bleeding and other adverse events. The investigators also accounted for the direct costs of drugs during hospital and post-hospitalization, physician visits, administration time, hospital admission/readmission and emergency services. They estimated indirect costs based on productivity loss for employed and unemployed patients.

        The recurrence rate of DVT in evaluable patients was enoxaparin 1.6 percent (2/125) and UFH 7.3 percent (8/110, p=0.049). The incidence of pulmonary embolism in evaluable patients was enoxaparin 0.0 percent (0/125) and UFH 3.7 percent (4/107, p=0.044). The incidence of major bleeding was enoxaparin 0.0 percent and UFH 2.0 percent (p=non-significant). The incidence of all bleeding events was enoxaparin 10.0 percent, and UFH 13.5 percent, (p=non-significant).

        The total direct costs in Australian dollars were $1363 for enoxaparin and $4058 for UFH. The total indirect costs were $1678 for enoxaparin and $1569 for UFH. The total costs were $3041 for enoxaparin and $5627 for UFH.

        "The main cost drivers were costs associated with hospital admission ($258 for enoxaparin and $2495 for UFH) and hospital readmission ($512 for enoxaparin and $1104 for UFH). Treatment with enoxaparin once daily at home led to an average direct cost saving of $2695 per patient. When indirect costs related to productivity loss were taken into account, the total cost saving was $2586 per patient," the authors reported.

        Dr. Chong also noted that, "We've had extreme difficulty getting nurses to patients twice a day. So the results of this study imply potential changes in patterns of treatment as well as comparing for costs."



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send